Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

US Department of Justice
Argus Health
McKinsey
McKesson
QuintilesIMS
Fish and Richardson
Merck
Cipla
Chinese Patent Office
Chubb

Generated: August 23, 2017

DrugPatentWatch Database Preview

Osi Pharms Company Profile

« Back to Dashboard

What is the competitive landscape for OSI PHARMS, and when can generic versions of OSI PHARMS drugs launch?

OSI PHARMS has one approved drug.

There are four US patents protecting OSI PHARMS drugs.

There are one hundred and twenty patent family members on OSI PHARMS drugs in fifty countries.

Summary for Applicant: Osi Pharms

Patents:4
Tradenames:1
Ingredients:1
NDAs:1
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Osi Pharms
TARCEVA
erlotinib hydrochloride
TABLET;ORAL021743-003Nov 18, 2004RXYesYes► Subscribe► Subscribe► Subscribe
Osi Pharms
TARCEVA
erlotinib hydrochloride
TABLET;ORAL021743-002Nov 18, 2004RXYesNo► Subscribe► SubscribeY► Subscribe
Osi Pharms
TARCEVA
erlotinib hydrochloride
TABLET;ORAL021743-001Nov 18, 2004RXYesNo► Subscribe► SubscribeY► Subscribe
Osi Pharms
TARCEVA
erlotinib hydrochloride
TABLET;ORAL021743-003Nov 18, 2004RXYesYes► Subscribe► SubscribeY► Subscribe
Osi Pharms
TARCEVA
erlotinib hydrochloride
TABLET;ORAL021743-003Nov 18, 2004RXYesYes► Subscribe► SubscribeY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for OSI PHARMS drugs

Drugname Dosage Strength Tradename Submissiondate
erlotinib hydrochloride
Tablets25 mg, 100 mg and 150 mg
TARCEVA
11/18/2008

International Patent Family for Osi Pharms Drugs

Country Document Number Estimated Expiration
Colombia4410333► Subscribe
Australia703638► Subscribe
Canada2632556► Subscribe
European Patent Office1110953► Subscribe
European Patent Office2163546► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Osi Pharms Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
00214Netherlands► SubscribePRODUCT NAME: ERLOTINIB, DESGEWENST IN DE; REGISTRATION NO/DATE: 57266 01,..02,..03EU/1/05/311/001...003 20050321
209Luxembourg► Subscribe91209, EXPIRES: 20200321
C/GB06/008United Kingdom► SubscribePRODUCT NAME: ERLOTINIB OR A PHARMACEUTICALLY ACCEPTABLE SALT OR POLYMORPH THEREOF, IN PARTICULAR THE HYDROCHLORIDE SALT; REGISTERED: CH 5726601 20050321; CH 5726602 20050321; CH 5726603 20050321; UK EU/1/05/311/001 20050919; UK EU/1/05/311/002 20050919; UK EU/1/05/311/003 20050919
2006Austria► SubscribePRODUCT NAME: ERLOTINIB UND SEINE PHARMAZEUTISCH ANNEHMBAREN SALZE, INSBESONDERE ERLOTINIBHYDROCHLORID; NAT. REGISTRATION NO/DATE: EU/1/05/311/001 - EU/1/05/311/003 20050919; FIRST REGISTRATION: CH 57266 01 - 57266 03 20050321
0817775/01Switzerland► SubscribeFORMER REPRESENTATIVE: BOHEST AG, CH
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

AstraZeneca
Queensland Health
Teva
UBS
Express Scripts
Citi
US Army
Moodys
Medtronic
Fuji

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot